drugset / Trial / NCT05926349

A Study of Andexanet Alfa in Patients Requiring Urgent Surgery or Procedure

NCT05926349

Phase 3 Withdrawn AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The study will aim to find out if the drug andexanet alfa is safe and effective in preventing major bleeding during urgent surgery or invasive procedures. The study will compare the use of andexanet alfa to the usual care given at the study center.

Timeline

Start
2024-08-02
Primary completion
2027-01-05
Completion
2027-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Andexanet alfa Protein / enzyme biologic Intravenous

Indications

No indication recorded.